Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Bioanalysis|December 24, 2011
Quantitation of therapeutic proteins following direct trypsin digestion of dried blood spot samples and detection by LC-MS-based bioanalytical methods in drug discoveryBogdan G Sleczka, Celia J D'Arienzo, Adrienne A Tymiak, et al.
Bioanalysis|May 23, 2012
A bioanalytical strategy utilizing dried blood spot sampling and LC-MS/MS in discovery toxicology studiesLorell Discenza, Mary T Obermeier, Richard Westhouse, et al.
Bioanalysis|September 6, 2012
What is next for dried blood spots?Qin C Ji, Guowen Liu, Celia J D'Arienzo, et al.
Bioanalysis|March 14, 2012
Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MSAsoka Ranasinghe, Ragu Ramanathan, Mohammed Jemal, et al.
Bioanalysis|November 19, 2010
DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitorsCelia J D'Arienzo, Qin C Ji, Lorell Discenza, et al.
Bioanalysis|August 27, 2014
Quantification of human mAbs in mouse tissues using generic affinity enrichment procedures and LC-MS detectionBogdan G Sleczka, John T Mehl, David J Shuster, et al.
Journal of Pharmaceutical Sciences|September 26, 2009
Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic propertiesZheng Yang, Lisa M Zadjura, Anthony M Marino, et al.
Bioanalysis|January 26, 2016
Ultrasensitive quantitative LC-MS/MS of an inhibitor of apoptosis protein's antagonist in plasma using protein target affinity extractionLorell N Discenza, Georgia Cornelius, Jinping Gan, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2012
Inhibitors of HIV-1 attachment. Part 9: an assessment of oral prodrug approaches to improve the plasma exposure of a tetrazole-containing derivativeKap-Sun Yeung, Zhilei Qiu, Zheng Yang, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2Robert M Borzilleri, Rajeev S Bhide, Joel C Barrish, et al.
Pageof 2